期刊文献+

来氟米特结合加味真武汤治疗糖尿病肾病的疗效观察 被引量:2

The clinical curative effects of Leflunomide and Jiawei Zhenwu decoction on diabetic nephropathy
下载PDF
导出
摘要 目的探讨来氟米特结合加味真武汤治疗阳虚型糖尿病肾病的临床疗效。方法 96例阳虚型糖尿病肾病患者随机分为两组:A组(对照组)48例,B组(治疗组)48例。两组均给予常规治疗,A组给予常规治疗的基础上加来氟米特治疗;B组给予常规治疗的基础上加用来氟米特及加味真武汤治疗。结果两组治疗前后中医辨证积分,治疗组24 h尿蛋白定量、胆固醇、血肌酐、血浆白蛋白各项指标较对照组改善明显,且肾功能好转及稳定优于对照组,差异有统计学意义(P<0.05)。结论来氟米特结合加味真武汤治疗糖尿病肾病有明显减少24 h尿蛋白定量、升高血浆白蛋白、降低血脂、稳定肾功能的作用,在防治和延缓糖尿病肾病中两者有协同作用,临床疗效满意,值得进一步研究。 Objective To investigate the clinical curative effects of Leflunomide and Jiawei Zhenwu decoction on dia- betic nephropathy. Methods 96 cases were randomly divided into control group (A group ,48 cases)and treatment group (B group ,48cases). Two groups were both treated by routine therapy, A group was treated by combination of routine therapy and Leflunomide, B group was treated by combination of routine therapy, Leflunomide and Jiawei Zhenwu decoction. Results Af- ter treatment, the Chinese medicine dialectical integral ,24 h nrine protein excretion, cholesterol, blood creatinine, serum albu- min of the treatment group obviously turned better than before, the improvement and stability of kidney function of treatment group were better than that of matched control,the difference had statistical significance. Conclusion Leflunomide and Jiawei Zhenwu decoction could obviously reduce 24 h nrine protein excretion, heat up serum albumin, lower serum lipids, stablilize kidney function, they had synergy in preventing, curing and defering diabetic nephropathy, the clinical curative effects was sati- sfactive and worth studying further.
作者 汪玉芹 肖丽
出处 《中国医学创新》 CAS 2011年第21期47-49,共3页 Medical Innovation of China
关键词 来氟米特 加味真武汤 糖尿病肾病 Leflunomide Jiawei Zhenwu decoction Diabetic nephropathy
  • 相关文献

参考文献7

二级参考文献25

  • 1王海燕.肾脏病学[M].北京:人民卫生出版社,1997.684.
  • 2王海燕.肾脏病学(第2版)[M].北京:人民卫生出版社,1997.1605.
  • 3北京 天津糖尿病协作组.糖尿病血管并发症的研究[J].中华肾脏病杂志,1989,5:134-134.
  • 4Kalden J,Schattenkirchner M,Sorensen H,et al.Five year follow-up:efficacy and safety of leflunomide in patients with active rhrumatoid arthritis.Arthritis & Rheumatism,2001,44(9):173-176.
  • 5Hansen KE,Cush J,Singhal A,et al.The safety and efficacy of leflunomide in combination with infliximab in rheumatoid arthritis.Arthritis Rheum,2004,51(2):228-232.
  • 6Jaimes-Hernandez J,Robles-San Roman M,et al.Rheumatoid arthritis treatment with weekly leflunomide:an open-label study.J Rheumatol,2004,31(2):235-237.
  • 7Williams JW,Mital D,Chong A,et al.Experiences with leflunomide in solid organ transplantation.Transplantation,2002,73(3):358-366.
  • 8Xu X,Shen J,Mall JW,et al.In vitro and in vivo antitumor activity of a novel immunomodulatory drug,leflunomide:mechanisms of action.Biochem Pharmacol,1999,58(9):1405-1413.
  • 9Manna SK,Aggarwal BB.Immunosuppressive leflunomide metabolite(A77 1726) blocks TNF-dependent nuclear factor-kappa B activation and gene expression.J Immunol,1999,162(4):2095-2102.
  • 10Urushibara M,Takayanagi H,Koga T,et al.The antirheumatic drug leflunomide inhibits osteoclastogenesis by interfering with receptor activator of NF-kappa B ligand-stimulated induction of nuclear factor of activated T cells c1.Arthritis Rheum,2004,50(3):794-804.

共引文献76

同被引文献22

引证文献2

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部